The association between fasting plasma insulin level and coronary heart disease (CHD) was studied in 909 non-insulin-dependent diabetic (NIDDM) patients, aged 45-64 years, and in 1,373 nondiabetic control subjects. Both diabetic and nondiabetic subjects with various manifestations of CHD had higher plasma insulin levels than did subjects free of CHD. By plasma insulin quintiles formed according to values in nondiabetic subjects, the age-adjusted prevalence of CHD defined by symptoms and/or electrocardiographic changes in diabetic men was 48.2% in quintiles I+II (lowest), 54.8% in quintiles III+IV, and 65.7% in quintile V (highest) ( / J = 0 . 0 0 6 ) . The respective prevalences in diabetic women were 53.5%, 59.1%, and 733% (p=0.004); in nondiabetic men, 28.1%, 33.7%, and 43-3%, respectively (p=0.016); and in nondiabetic women, 28.1%, 34.9%, and 44.3%, respectively (p=0.007). An essentially similar association was observed between plasma insulin level and definite or possible myocardial infarction (MI). In diabetic subjects, a positive association between plasma insulin level and CHD manifestations was also found when insulin strata were formed using quintile cutoff points determined separately from diabetic subjects. The association between plasma insulin level and the prevalence of CHD or MI disappeared or was weaker, especially in men, when adjustment was made for body mass index, hypertension, and triglyceride or high density lipoprotein (HDL) cholesterol level. The association between high plasma insulin level and CHD was significant in diabetic subjects with a body mass index greater than 27 kg/m 2 but not in those diabetics with a body mass index less than or equal to 27 kg/m 2 . A significant clustering of hypertension, high triglyceride values, and low HDL cholesterol levels was observed in diabetic subjects in the highest insulin quintiles. The results suggest that hyperinsulinemia is an indicator of CHD in both NIDDM patients and nondiabetic subjects. Hyperinsulinemia may be directly atherogenic, but it is more probable that hyperinsulinemia reflects insulin resistance, which may be a factor enhancing atherogenesis by causing adverse changes in many CHD risk factors. (Arteriosclerosis and Thrombosis 1991;ll:80-90)
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The association between fasting plasma insulin level and coronary heart disease (CHD) was studied in 909 non-insulin-dependent diabetic (NIDDM) patients, aged 45-64 years, and in 1,373 nondiabetic control subjects. Both diabetic and nondiabetic subjects with various manifestations of CHD had higher plasma insulin levels than did subjects free of CHD. By plasma insulin quintiles formed according to values in nondiabetic subjects, the age-adjusted prevalence of CHD defined by symptoms and/or electrocardiographic changes in diabetic men was 48.2% in quintiles I+II (lowest), 54.8% in quintiles III+IV, and 65.7% in quintile V (highest) ( / J = 0 . 0 0 6 ) . The respective prevalences in diabetic women were 53.5%, 59.1%, and 733% (p=0.004); in nondiabetic men, 28.1%, 33.7%, and 43-3%, respectively (p=0.016); and in nondiabetic women, 28.1%, 34.9%, and 44.3%, respectively (p=0.007). An essentially similar association was observed between plasma insulin level and definite or possible myocardial infarction (MI). In diabetic subjects, a positive association between plasma insulin level and CHD manifestations was also found when insulin strata were formed using quintile cutoff points determined separately from diabetic subjects. The association between plasma insulin level and the prevalence of CHD or MI disappeared or was weaker, especially in men, when adjustment was made for body mass index, hypertension, and triglyceride or high density lipoprotein (HDL) cholesterol level. The association between high plasma insulin level and CHD was significant in diabetic subjects with a body mass index greater than 27 kg/m 2 but not in those diabetics with a body mass index less than or equal to 27 kg/m 2 . A significant clustering of hypertension, high triglyceride values, and low HDL cholesterol levels was observed in diabetic subjects in the highest insulin quintiles. The results suggest that hyperinsulinemia is an indicator of CHD in both NIDDM patients and nondiabetic subjects. Hyperinsulinemia may be directly atherogenic, but it is more probable that hyperinsulinemia reflects insulin resistance, which may be a factor enhancing atherogenesis by causing adverse changes in many CHD risk factors. (Arteriosclerosis and Thrombosis 1991;ll:80-90) P rospective studies have shown that elevated levels of fasting and/or postglucose plasma insulin are associated with an increased risk of coronary heart disease (CHD) in nondiabetic subjects, and this risk is independent of other CHD risk factors. 1 -3 In patients with non-insulin-dependent diabetes mellitus (NIDDM), there is a large variability in fasting and postglucose plasma insulin levels, 4 and cross-sectional studies have demonstrated that NIDDM patients with atherosclerotic vascular disease have higher levels of fasting plasma insulin than do those without atherosclerotic vascular disease. 5 -7 Prospective studies of the association between high plasma insulin levels and CHD in NTDDM patients are scant and show contradictory results, one study showing a positive association 6 and one study suggesting an inverse association between 2-hour postglucose plasma insulin level and the risk of CHD. 8 The purpose of the present study was to determine whether there is a similar association between fasting plasma insulin level and various manifestations of CHD in NIDDM patients and nondiabetic subjects and whether the possible association in NIDDM patients extends over the whole range of their plasma insulin concentrations. Moreover, we wanted to determine whether the possible association between insulin level and CHD would be modified by obesity and whether other CHD risk factors would cluster in diabetic and nondiabetic subjects having high plasma insulin levels.
Methods

Subjects
During 1982-1984, a cross-sectional study was performed in East and West Finland to compare the prevalence of atherosclerotic vascular disease and its risk factors in middle-aged diabetic patients and in nondiabetic subjects. The detailed description of recruitment of the study populations has been reported previously. 9 The original diabetic study population was chosen from the national register of the Social Insurance Institution, which includes practically all Finnish citizens who receive antidiabetic medication. 10 Briefly, the inclusion criteria were the following: 1) age from 45 to 64 years, 2) diabetes diagnosed at the age of 30 years or later, and 3) area of residence and place of birth in the Kuopio University Central Hospital district (East Finland) or in the Turku University Central Hospital district (West Finland). The presence of diabetes in subjects listed on the register was ascertained as follows. Physicians' certificates, by which the patients had obtained their antidiabetic drugs free of charge, were checked for every patient in our study whose fasting plasma glucose level was less than 8 mmol/1 to confirm that World Health Organization (WHO) diagnostic criteria had been met. Those 30 patients whose diagnosis of diabetes could not be verified on the basis of physicians' certificates underwent an oral glucose tolerance test (75 g glucose), and 19 patients having 2-hour plasma glucose levels less than 11.0 mmol/1 were excluded. Altogether, 562 diabetic patients from East Finland and 625 diabetic patients from West Finland participated in our study, yielding participation rates of 83% and 79% in East and West Finland, respectively. Of these patients, 120 subjects from East Finland and 158 subjects from West Finland were receiving insulin treatment at the time of examination, and these subjects were excluded from the analyses. The final diabetic study population consisted of 229 men and 213 women from East Finland and 273 men and 194 women from West Finland. Eighty-four patients in East Finland and 63 patients in West Finland were treated with diet only, and 358 patients in East Finland and 404 patients in West Finland were treated with oral hypogrycemic drugs. Of those receiving oral drugs, 76.7% were treated with a sulfonylurea only, 1.4% were treated with metformin only, and 21.9% were treated with a combination therapy of a sulfonylurea and metformin.
A random control sample of subjects whose place of birth was the Kuopio University Central Hospital district (East Finland) or the Turku University Central Hospital district (West Finland) and who were living in these areas was taken from the population register containing all subjects aged 45-64 years. Altogether, 313 nondiabetic men and 336 nondiabetic women from East Finland and 325 nondiabetic men and 399 nondiabetic women from West Finland participated in the study, yielding participation rates of 79% and 85% in East and West Finland, respectively. Subjects with diabetes were excluded on the basis of fasting plasma glucose levels. The representativeness of the participants was, in our opinion, good for the following reasons: 1) The participation rate was 81% in diabetic and 82% in nondiabetic subjects. 2) Among both diabetic and nondiabetic subjects, the participating and nonparticipating individuals were similar with respect to age, proportion of subjects on invalidity pension, proportion of subjects receiving free medication for treatment of cardiac failure or hypertension, and for diabetic subjects, were similar with respect to duration and mode of treatment of diabetes. All subjects gave their informed consent to the study. Approval for this study was given by the ethics committees of the University of Kuopio and the University of Turku.
Assessment of Coronary Heart Disease
The study program was performed during one outpatient visit to the Rehabilitation Research Centre of the Social Insurance Institution in Turku or to the Clinical Research Unit of the University of Kuopio. The study protocol was in accordance with the appropriate institutional guidelines.
Angina pectoris and severe chest pain attack were assessed by Rose's cardiovascular questionnaire.
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All medical records of those subjects who reported that they had been admitted to the hospital on the basis of chest pain were reviewed. A conventional 12-lead resting electrocardiogram (ECG) was recorded between 8 and 9 AM after a 12-hour fast. ECG abnormalities were classified according to the Minnesota code. 1112 The WHO criteria for definite and possible myocardial infarction (MI) based on symptoms, ECG changes, and enzyme determinations were used in the ascertainment of previous MI. 13 The diagnostic categories and their definitions used for different manifestations of CHD were as follows: Body mass index (BMI) was calculated from the formula BMI=weight (kg)/height (m) mm Hg, or diastolic blood pressure greater than or equal to 95 mm Hg. Details of blood pressure measurement have been described elsewhere. 9 If we had used a systolic blood pressure greater than or equal to 140 mm Hg or diastolic blood pressure greater than or equal to 90 mm Hg as the hypertension limit, the prevalence of hypertension would have been 76.9% in diabetic men, 86.2% in diabetic women, 55.8% in nondiabetic men, and 62.2% in nondiabetic women. Patients were asked to categorize themselves in one of three categories with respect to their physical exercise habits. The definition of the third category was regular physical activity during leisure time for at least 30 minutes at least twice a week, and inclusion in this category was taken as the criterion for physical activity. Smoking habits and alcohol consumption were defined as current smoking, or alcohol consumption of at least 6 g/week.
Biochemical Methods
All blood specimens were taken at 8 AM after a 12-hour fast, with no interruption of drug treatment. Laboratory determinations were performed in duplicate. Plasma insulin level was determined by a commercial radioimmunoassay method (antisera M8170 and M8309, Novo, Copenhagen, Denmark). The day-to-day and intra-assay variations were 8.4% and 7.0%, respectively. Plasma glucose level was measured by the glucose oxidase method (Boehringer, Mannheim, F.R.G.). Serum total cholesterol and triglycerides were determined enzymatically (Boehringer). The day-to-day variation was 2.2% in cholesterol measurement and 4.4% in triglyceride measurement; the intra-assay variation was 1.6% in cholesterol and 2.6% in triglycerides. Serum high density lipoprotein (HDL) cholesterol was determined enzymatically after precipitation of low density lipoproteins and very low density lipoproteins with dextran sulfate.
14 The day-to-day and intraassay variations for HDL cholesterol were 3.8% and 1.7%, respectively.
Statistical Methods
Univariate statistical analyses of the data were performed with SAS computer programs (SAS Institute, Cary, N.C.), as well as programs developed at the Social Insurance Institution. Student's t test (continuous variables) or \ 2 te st (categorical variables) was used to test the significance of the difference between two groups, and an analysis of variance (ANOVA) or x 1 test was used for the comparison of more than two groups. Pearson's (continuous variables) or Spearman's (categorical variables) correlation coefficients were calculated to indicate the correlations between plasma insulin levels and other variables. Because of their skewed distributions, insulin and triglyceride levels were applied after logarithmic transformation.
Age-adjusted prevalence rates were calculated by a direct standardization method 15 for four 5-year age groups by using the total 1980 Finnish population, aged 45-64 years, as a standard population. The F test was used to test differences of prevalences, thus controlling for the effect of age. 16 The association of insulin level and CHD was also assessed after division of plasma insulin levels into quintiles. The analyses were performed after combining subjects from East and West Finland using SAS procedure CATMOD. 17 In this model for categorical variables, the logarithm of the CHD rate is a linear function of age and other explanatory variables.
Multivariate logistic analyses based on the maximum-likelihood method and the Wald test were calculated with SAS computer programs (SAS Institute).
Results
Characteristics of the study populations are shown in Table 1 . Diabetic patients were older and more obese than were nondiabetic subjects. Fasting plasma insulin levels were significantly higher in diabetic subjects than in controls. The cutoff point for the lowest decile and the median value in diabetic patients were as follows: East Finland men, 9.7 and 17.9 milliunits/1, respectively and women, 10.1 and 21.6 milliunits/1, respectively; West Finland men, 8.8 and 17.4 milliunits/1, respectively, and women, 10.4 and 18.5 milliunits/1, respectively. The corresponding values for nondiabetic subjects were East Finland men, 8.1 and 14.1 milliunits/1, respectively, and women, 9.6 and 14.4 milliunits/1, respectively; West Finland men, 7.3 and 11.3 milliunits/1, respectively, and women, 6.9 and 11.0 milliunits/1, respectively. Diabetic subjects had lower serum HDL cholesterol levels, higher triglyceride levels, and a higher prevalence of hypertension than did nondiabetics. Subjects in East Finland tended to have higher fasting plasma insulin and serum total cholesterol and triglyceride values than did subjects in West Finland. There were no other consistent East-West differences in CHD risk factor levels.
Fasting plasma insulin levels were positively correlated with fasting plasma glucose levels in nondiabetic subjects (r values varied in the four groups by sex and area of residence, from +0.22 to +0.43,p for each <0.001) but not in NIDDM patients. Accordingly, in all diabetic patient groups subdivided by sex and area, the mean plasma glucose level was above 10.0 mmol/1 in all insulin deciles and did not differ between the deciles. There was a positive correlation between plasma insulin level and BMI (r values varied in diabetic subjects from +0.22 to +0.66,p for each <0.001, and in nondiabetic subjects from +0.40 to +0.55, p for each <0.001, the logarithm of serum triglyceride (r values varied in diabetic subjects from +0.27 to +0.41, p for each <0.001, and in nondiabetic subjects from +0.36 to +0.42, p for each < 0.001), and the prevalence of hypertension (rvalues varied in diabetic subjects from +0.13 to +0.34, p for each <0.05, and in nondiabetic subjects from +0.13 to +0.24, p for each <0.05). Plasma insulin level was inversely correlated with serum HDL cholesterol level (rvalues varied in diabetic subjects from -0.29 Values are mean±SD. All statistical comparisons were performed after adjustment for age, and insulin and triglyceride levels were applied after logarithmic transformation. Samples for biochemical determinations were taken after an overnight fast.
HDL, high density lipoprotein.
to -0.36, p for each < 0.001, and in nondiabetic subjects from -0.22 to -0.30, p for each <0.001). There were no consistent associations between plasma insulin level and serum cholesterol level, smoking status, physical activity, or alcohol intake. Diabetic men and women with definite MI and those with definite or possible MI had higher fasting plasma insulin levels than did those without these manifestations of CHD although in diabetic women from West Finland, the difference was not statistically significant with respect to either of the two diagnostic categories (Table 2) . A tendency toward a similar difference was seen among nondiabetic subjects except for men from West Finland. Both diabetic and nondiabetic subjects with ischemic ECG changes (excluding patients with Minnesota code 1.1 or 1.2) had higher plasma insulin levels than did those without these ischemic ECG changes. A tendency toward a similar difference in plasma insulin level was found between subjects with and those without angina pectoris (excluding patients with definite MI). Both diabetic and nondiabetic subjects from both areas who had CHD symptoms and/or ischemic ECG changes had higher plasma insulin concentrations than did those without these criteria of CHD. Further analyses of the association between insulin level and CHD were performed by dividing the study groups into quintiles of plasma insulin level. Subjects from East and West Finland were first analyzed separately, but because the results were essentially similar in both study areas, subjects from East and West Finland were combined in all subsequent analyses. Stratification according to fasting plasma insulin level was also performed using insulin tertiles or quartiles, but since the association between insulin level and MI or insulin level and CHD seemed to be nonlinear, division into quintiles and the combination of the two lowest quintiles and of the third and fourth quintiles were used to analyze these associations. To determine whether absolute insulin level was associated with MI and CHD, insulin quintile cutoff points calculated from nondiabetic subjects (pooled insulin values for men and women from both areas) were also used for diabetic subjects. In these analyses, a high plasma insulin level was significantly associated with definite or possible MI in diabetic men and in nondiabetic women and with CHD in both male and female diabetic and nondiabetic subjects (Figures 1 and 2 ).
To investigate whether the association between high plasma insulin level and CHD extends over the whole range of plasma insulin distribution in NIDDM patients, we performed analyses using the insulin quintile cutoff points determined separately from diabetic subjects (pooled insulin values for men and women from both areas). In these analyses, the age-adjusted prevalence of definite or possible MI and the age-adjusted prevalence of CHD symptoms and/or ischemic ECG changes increased with increasing insulin level in both male and female NIDDM patients (for definite or possible MI, /7=0.OO2 for men andp=0.052 for women; for CHD by symptoms and/or ECG, p=0.003 for men and p=0.030 for women).
To determine whether the association between plasma insulin level and CHD was modified by obesity, diabetic and nondiabetic subjects were divided according to BMI using a cutoff point of 27 kg/m 2 and, with respect to plasma insulin level, into high-and low-insulin groups according to values in all nondiabetic subjects pooled together. The association between plasma insulin level and MI or plasma insulin level and CHD by symptoms and/or ECG was 
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significant in obese diabetic subjects but not in nonobese diabetic subjects (Table 3 ). In contrast, in these analyses plasma insulin level was not significantly related to MI or CHD in either obese or nonobese nondiabetic subjects. Obesity was more consistently related to CHD manifestations in subjects with high insulin levels than in those with low insulin values, particularly in men. The association between plasma insulin level and obesity in relation to CHD manifestations was also studied using division of combined insulin values into quintiles as in Figures 1 and  2 . In these analyses, insulin level was not significantly related to MI or CHD in either obese or nonobese diabetic subjects (data not shown).
To investigate whether high plasma insulin level was associated with a high frequency of other CHD risk factors, we calculated the proportion (percent) of subjects with various CHD risk factors related to insulin resistance (low HDL cholesterol levels, high triglyceride values, or hypertension) among the diabetic and nondiabetic subjects belonging to various insulin quintiles (Table 4) . In this analysis, a low HDL cholesterol level was defined as the upper limit of the lowest HDL cholesterol tertile, and a high triglyceride value was defined as the lower limit of the highest triglyceride tertile for nondiabetic subjects. Among diabetic subjects there was a marked clustering of CHD risk factors in the highest insulin quintiles. Among nondiabetic subjects there was a clear tendency for subjects in the lowest insulin quintile to have none of the other CHD risk factors. These two findings were seen in both obese and nonobese subjects.
The association between insulin level (stratified into quintiles I+11, III+IV, and V according to values in nondiabetic subjects) and CHD manifestations was also studied in analyses after excluding smokers and users of antihypertensive drugs. When The cutoff point for high and low insulin was 14.2 milliunits/1, i.e., the mean value of all nondiabetic subjects pooled together. The number of prevalent cases per total number of subjects are shown in parentheses.
FIGURE 2. Bar graph showing age-adjusted prevalence (%) of coronary heart disease symptoms and/or ischemic electrocardiographic changes according to fasting plasma insulin quintiles (I+11, III+IV, V). The quintile cutoff points determined from nondiabetic subjects (pooled insulin values for men and women from East and West
BMI, body mass index; CHD, coronary heart disease; ECG, electrocardiogram; MI, myocardial infarction.
•Comparison between subjects with BMI >27 kg/m 2 and BMIS27 kg/m 2 . tComparison between subjects with low and high insulin values.
users of antihypertensive drugs were excluded, the significant association between insulin level and MI or insulin level CHD disappeared in diabetic men, whereas the associations in other groups were largely unaffected (Table 5 ). When smokers were excluded, there was no significant association between plasma insulin level and MI in any of the groups, whereas the association between insulin level and CHD was significant in all groups. The association between insulin level and CHD manifestation was also studied in multivariate analyses including factors related to insulin resistance, that is, hypertension, BMI, and triglyceride and/or HDL cholesterol level (Table 5) . In these analyses, the association between insulin level and MI and between insulin level and CHD disappeared in both diabetic and nondiabetic men. In women, the association between insulin level and CHD manifestations remained unchanged except for the association between CHD by symptoms and/or ECG and insulin level in nondiabetic women, which was no longer significant after the adjustment.
The possible interaction between hypertension and insulin level in relation to the prevalence of definite or possible MI, or CHD by symptoms and/or ECG changes was studied by logistic regression analysis with the age factor included in the model. No statistically significant interaction was found between hypertension and insulin level in any of the four groups -diabetic and nondiabetic subjects, men and women.
In diabetic subjects, in multivariate analyses including known duration of diabetes and age, duration of diabetes was not significantly associated with the prevalence of definite or possible MI, or CHD by symptoms and/or ECG (p in all groups >0.12).
Discussion
The main purpose of this study was to determine whether the association between fasting plasma insulin level and CHD manifestations is similar in nondiabetic subjects and NIDDM patients. To investigate this issue, two types of analyses were made: first, comparisons of insulin levels between subjects with and without CHD and, second, comparisons of CHD prevalences in subjects stratified by plasma insulin concentrations. Fasting plasma insulin level was higher in diabetic subjects having CHD by virtually all diagnostic criteria compared with those of subjects free of CHD. This is in accordance with the study of Hillson and coworkers 6 that showed higher fasting plasma insulin levels in NIDDM patients with ECG abnormalities compared with those with normal ECGs. The difference in fasting plasma insulin levels between nondiabetic subjects with and without CHD tended to be similar to that in diabetic subjects. However, the statistical significances of these differences were weaker in nondiabetic subjects, possibly due to smaller numbers of prevalent cases. It is also possible that in nondiabetic subjects, differences between subjects with and without CHD manifestations would have been greater if the 2-hour Coronary heart disease risk factors include high total triglyceride values, low high density lipoprotein cholesterol values, and hypertension. Fasting plasma insulin quintiles (I, H, III, FV, V) and their cutoff points were calculated separately for nondiabetic subjects and diabetic patients.
p values indicate significance for the difference in the distribution of risk factors between insulin classes. Insulin values in the various classes for diabetic subjects were I+II, <16.4milliunits/l; m+IV, 16.4-30.0 milliunits/1; V, >30.0 milh'units/1; for nondiabetic subjects I+n, <113 milliunits/1; III+IV, 11.3-18.6 milliunits/1; V, >18.6 milliunits/1. High total trigrycerides for men were >1.64 mmol/1 and for women, >1.47 mmol/1 (lower limit of highest tertile in nondiabetic subjects). Low HDL cholesterol for men was <1.18 mmol/1 and for women, <1.44 mmol/1 (upper limit of lowest tertile in nondiabetic subjects).
In a similar analysis for diabetic patients where insulin classes were formed using the cutoff points for nondiabetic subjects, the results were essentially similar to those shown in the table.
postglucose insulin values had been measured instead of fasting values. than did nondiabetic subjects, suggesting that the higher prevalence of CHD in diabetic compared with nondiabetic subjects is not explained by plasma insulin levels. When diabetic patients were studied by dividing them into insulin quintiles using cutoff points determined from the plasma insulin distribution of diabetic subjects, a significant association between plasma insulin level and CHD manifestations was again observed. All these findings are compatible with the hypothesis that absolute plasma insulin level is a risk indicator of CHD in both diabetic and nondiabetic subjects. In addition, the positive association between plasma insulin level and CHD appears to extend to diabetic subjects over the whole range of their plasma insulin distribution. Our results are in accordance with the findings of the Paris Prospective Study, which showed that high plasma insulin level predicts the risk of CHD death in both NIDDM patients and nondiabetic subjects. 18 Our study population, which also included women, had a high prevalence of CHD manifestations. Therefore, our results suggest that plasma insulin level is an indicator of CHD even in populations with high CHD rates. In our study, the association between plasma insulin level and CHD was similar in men and women. In the Busselton study, 19 plasma insulin level was associated with all-cause mortality in older men but not in women. The different results in the Busselton study 19 and our study with regard to the sex difference in the risk factor nature of insulin level may be due to different study designs, that is, cross sectional versus prospective.
Two main hypotheses should be considered to explain the association between high plasma insulin level and CHD. First, insulin may be directly atherogenic, as suggested by animal studies that have shown increased synthesis of arterial lipids during hyperinsulinemia 20 and by in vitro studies that have shown that insulin level is mitogenic for cultured monkey and human arterial smooth muscle cells. 21 - 22 Second, since hyperinsulinemia is often associated with insulin resistance in both NIDDM and nondiabetic subjects, 23 the association between high plasma insulin level and CHD could be due to insulin resistance and not to insulin concentration per se. In accordance with earlier studies, 24 -26 we found a clustering of other CHD risk factors related to insulin resistance in subjects with high insulin concentration (high triglyceride values, low HDL cholesterol levels, and hypertension). Previous studies have suggested that high plasma insulin level is an independent risk factor for CHD. 2 However, since insulin resistance leads to high plasma insulin levels and is associated with low HDL values, high triglyceride values, and hypertension, 27 the possibility must be considered that insulin resistance would be the underlying factor for the association between high plasma insulin level and CHD. In our study, the association between plasma insulin level and CHD disappeared in diabetic men but was preserved in diabetic women when adjustment was made for other factors related to insulin resistance, that is, BMI, hypertension, and triglyceride or HDL cholesterol values. This suggests a sex difference in the nature of the association between plasma insulin level and CHD in diabetic subjects.
Obesity is known to be related to insulin resistance. 23 In accordance with this idea, we found a significant positive correlation between plasma insulin level and BMI in both diabetic and nondiabetic subjects. On the other hand, the association between plasma insulin level and CHD was significant in obese diabetics but not in nonobese diabetic individuals. It is also remarkable that obesity was related to CHD more consistently in the presence of hyperinsulinemia than without hyperinsulinemia. These findings are consistent with the results of the Paris Prospective Study 28 and the Israeli GOH Study. 29 The reason for the interaction between BMI and insulin level in relation to CHD is not known. However, the interaction does not seem to be associated with other CHD risk factors since in both diabetic and nondiabetic study groups, hypertension, low HDL cholesterol value, and high triglyceride value occurred more frequently in subjects with high plasma insulin levels than in those with low plasma insulin concentrations, irrespective of obesity (i.e., similarly in individuals with BMI >27 kg/m 2 and in those with BMI ^27 kg/m 2 ).
In the Paris Prospective Study, subjects with high insulin levels had higher CHD mortality rates than did those with low values among both normotensive and hypertensive subjects, but this trend was more clearly defined among hypertensive subjects. 28 In our study, no significant interaction was found between hypertension and insulin level in relation to CHD manifestations. Possible explanations for this different result between the two studies include differences in the criteria for hypertension and in the study design (cross sectional versus prospective).
Cross-sectional and longitudinal studies have shown that after a long duration of NIDDM, insulin secretion by the pancreas may be exhausted, leading to a decline in plasma insulin levels. 4 - 30 Thus, in our cross-sectional study of patients with varying durations of NIDDM, patients having relatively low plasma insulin levels at the time of examination might have had higher values earlier. Such a heterogeneity in our series of diabetic patients would, however, weaken the positive association between plasma insulin level and CHD; yet, we observed this association in both male and female diabetic patients. The importance of plasma insulin level as a CHD risk indicator in diabetic subjects is still strengthened by our finding that the association between insulin level and CHD was independent of the known duration of diabetes. In contrast to the situation in NIDDM patients, in nondiabetic subjects fasting plasma insulin level reflects insulin sensitivity and is usually not dependent on insulin secretion capacity.
In conclusion, our results suggest that hyperinsulinemia is an indicator of CHD in both NIDDM patients and nondiabetic subjects. Hyperinsulinemia may be directly atherogenic, but it is also possible that hyperinsulinemia merely reflects insulin resistance, which may be a crucial factor in atherogenesis by causing adverse changes in many CHD risk factors.
